哈藥股份(600664.SH)因哈藥集團增資擴股致全面要約收購要約價為3.83元/股
格隆匯8月15日丨哈藥股份(600664.SH)公佈，2019年8月14日，公司收到哈藥集團有限公司(“哈藥集團”)送交的《哈藥集團股份有限公司要約收購報告書摘要》。
根據該摘要，2019年8月9日，重慶哈珀股權投資基金合夥企業(有限合夥)(“重慶哈珀”)、天津黑馬祺航投資管理有限公司(“黑馬祺航”)與哈藥集團原股東簽署增資協議，分別以現金人民幣約8.0529億元、約4.0265億元對哈藥集團進行增資，分別認繳哈藥集團新增註冊資本約4.3529億元、約2.1765億元，分別佔本次增資後哈藥集團的股權比例為10.00%、5.00%。此次增資完成後，哈藥集團股權結構為，哈爾濱市人民政府國有資產監督管理委員會(“哈爾濱市國資委”)持股38.25%，中信資本冰島投資有限公司、華平冰島投資有限公司、黑龍江中信資本醫藥產業股權投資合夥企業(有限合夥)分別持股19.125%、18.70%、0.425%，哈爾濱國企重組管理顧問有限公司持股8.50%，重慶哈珀持股10.00%，黑馬祺航持股5.00%。
此次增資完成後，哈藥集團的控制權將發生變更，公司實際控制人將由哈爾濱市國資委變更為無實際控制人。
由於哈藥集團為公司的控股股東，持有公司已發行股份的46.49%，此次全面要約收購系因哈藥集團進行增資擴股，履行因重慶哈珀和黑馬祺航將通過增資方式分別取得哈藥集團10%和5%的股權導致哈藥集團層面股東結構發生重大變化而觸發的要約收購義務。此次要約收購的主要目的係為賦予投資者充分選擇權。根據《證券法》和《上市公司收購管理辦法》，哈藥集團應當向除哈藥集團之外的其他所有持有上市公司流通普通股(A股)的股東發出全面要約。
基於要約價格為3.83元/股的前提，此次要約收購所需最高資金總額約51.08億元。作為本次要約的收購人，哈藥集團已於本報告書摘要公告前將約10.27億元(不少於要約收購所需最高資金總額的20%)存入中國結算上海分公司指定的銀行賬户，作為本次要約收購的履約保證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
